The COVID-19 pandemic has provided US regulators with a unique opportunity to test whether they can successfully use remote monitoring to evaluate the performance of firms making software as a medical device (SaMD). So far, it seems it is a viable option, a new report says.
The US Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) published a report on 14 September updating stakeholders of the progress it’s made with its Precertification (Pre-Cert) Program, and what its next steps are
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?